Cosunter(SZ:300436) Xin Lang Cai Jing·2025-09-10 03:05Group 1 - The core point of the article highlights the recent decline in Guangshentang's stock price, which fell by 5.03% to 144.31 CNY per share, with a trading volume of 1.535 billion CNY and a turnover rate of 7.51%, resulting in a total market capitalization of 22.984 billion CNY [1] - Guangshentang Pharmaceutical Co., Ltd. is based in Fuzhou, Fujian Province, and specializes in the research, production, and sales of nucleoside antiviral drugs for hepatitis B, with 98.54% of its revenue coming from liver and gallbladder disease medications [1] Group 2 - Among the top ten circulating shareholders of Guangshentang, a fund under China Europe Fund, specifically the China Europe Medical Health Mixed A (003095), increased its holdings by 393,100 shares in the second quarter, now holding 1.8447 million shares, which accounts for 1.35% of the circulating shares [2] - The China Europe Medical Health Mixed A fund has a current scale of 15.638 billion CNY and has achieved a year-to-date return of 31.12%, ranking 1981 out of 8194 in its category, with a one-year return of 46.49%, ranking 2733 out of 7962 [2]